Xenon Pharmaceuticals (XENE) analyst forecast and price target
Analyst forecast
Consensus of 18 analyst ratings
Based on 7 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Guggenheim | Initiated Coverage | Buy | $73.00 | Oct 6, 2026 |
| Baird | Maintained | Outperform | $90.00 from $97.00 | Sep 18, 2026 |
| Needham | Maintained | Buy | $60.00 from $78.00 | Sep 18, 2026 |
| Deutsche Bank | Downgraded | Buy → Hold | $46.00 from $90.00 | Sep 18, 2026 |
| Wells Fargo | Maintained | Overweight | $64.00 from $69.00 | Sep 18, 2026 |
| Wedbush | Maintained | Outperform | $55.00 from $71.00 | Sep 18, 2026 |
| RBC Capital | Maintained | Outperform | $70.00 from $81.00 | Sep 18, 2026 |
| RBC Capital | Maintained | Outperform | $81.00 from $82.00 | Aug 7, 2026 |
| JP Morgan | Maintained | Overweight | $82.00 from $80.00 | May 27, 2026 |
| JP Morgan | Maintained | Overweight | $80.00 from $77.00 | May 12, 2026 |
| Needham | Maintained | Buy | $78.00 from $80.00 | May 8, 2026 |
| RBC Capital | Maintained | Outperform | $82.00 from $80.00 | May 8, 2026 |
| Wedbush | Maintained | Outperform | $63.00 from $64.00 | Mar 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $74.00 from $53.00 | Mar 10, 2026 |
| Deutsche Bank | Maintained | Buy | $90.00 from $56.00 | Mar 10, 2026 |
| Wedbush | Maintained | Outperform | $64.00 from $47.00 | Mar 10, 2026 |
| Wells Fargo | Maintained | Overweight | $68.00 from $49.00 | Mar 10, 2026 |
| Baird | Maintained | Outperform | $97.00 from $63.00 | Mar 9, 2026 |
| Needham | Maintained | Buy | $80.00 from $58.00 | Mar 9, 2026 |
| Wells Fargo | Maintained | Overweight | $49.00 from $48.00 | Feb 27, 2026 |
Frequently asked questions
What is the price target for XENE stock?
The average 12-month analyst price target for Xenon Pharmaceuticals (XENE) is $65.43, with a high estimate of $90.00 and a low of $46.00, across 7 analysts.
Is XENE a buy, sell, or hold?
Analysts covering Xenon Pharmaceuticals currently average a Buy rating: 18 buy, 0 hold and 0 sell, from 18 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for XENE?
The average price target of $65.43 implies 93.00% upside from the last price of $33.90.
What is the latest analyst rating on XENE?
On Oct 6, 2026, Guggenheim initiated coverage of Xenon Pharmaceuticals at Buy with a price target of $73.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.